Kendra Nordgren, PhD

Assistant Professor, Medical School, Duluth Campus

Kendra Nordgren

Contact Info

Office Phone 218-726-7432

Fax 218-726-7937

Office Address:
Department of Biomedical Sciences
211 SMed
1035 University Dr
Duluth, MN 55812

Assistant Professor, Medical School, Duluth Campus

Department of Biomedical Sciences

PhD, Molecular Pharmacology & Experimental Therapeutics, Mayo Graduate School, 2011

B.S. (Honors), University of Wisconsin River Falls, 2006

Postdoctoral Associate in Toxicology, University of Minnesota Medical School, Duluth, MN, 2011-2013


Awards & Recognition

University of Minnesota

  • Faculty Award for Collaborative Teaching, University of Minnesota Medical School Duluth, Department of Biomedical Sciences, 2014
  • Registration Scholarship for the 2015 Association of American Medical Colleges’ Early Career Women Faculty Professional Development Seminar ($1,731) University of Minnesota Medical School, Office of Faculty Affairs, 2015

External Sources

  • Phi Kappa Phi National Honors Society (elected) 2006

Professional Associations

  • American Physiological Society 2015 – present
  • American Society for Pharmacology and Experimental Therapeutics, 2015 – present
  • International Association of Medical Science Educators, 2013 – present
  • Lillehei Heart Institute, University of Minnesota, 2013 – present
  • American Heart Association Professional Member, 2012 – present
  • Society of Toxicology (SOT) Associate Member, 2012 – present
  • Northland Regional Chapter of SOT (NLSOT), 2011 – present                     
  • Postdoctoral Representative NLSOT (elected), 2013 – 2014
  • American Association for the Advancement of Science, 2007 – present
  • American Society of Clinical Pharmacology and Therapeutics, 2007-present
  • Phi Kappa Phi National Honors Society, 2006-present


Research Summary/Interests

Doxorubicin is a widely used, effective anti-cancer therapeutic that is known to inhibit mitochondrial function causing mitochondrial toxicity. Unfortunately, a common, life-threatening side effect of doxorubicin is a dose-dependent, cumulative, and irreversible cardiotoxicity that often leads to dilated cardiomyopathy and congestive heart failure. Recent evidence suggests that epigenetic mechanisms may play an important role in the persistent and irreversible nature of this toxicity. The hypothesis under investigation is that cumulative and irreversible mitochondrial toxicity (and thus, cardiomyopathic risk) induced by doxorubicin therapy is the result, at least in part, of epigenetic alterations to the DNA methylation status of critical regulators to mitochondrial viability, function, and capacity.


See full list of publications at: PubMed



Course Director- Cardiovascular, Respiratory, Renal, Acid-Base - CRRAB 1 & CRRAB 2


Board Certifications

  • AAMC Medical Education Research Certificate May 2015
  • Diplomat of the American Board of Toxicology (In Progress)                     Expected October 2017